Literature DB >> 20646962

The trypanolytic factor-mechanism, impacts and applications.

Richard J Wheeler1.   

Abstract

The Trypanosoma brucei subspecies T. brucei brucei is non-human infective due to susceptibility to lysis by trypanolytic factor (TLF) in human serum. Reviewed here are the advances which have revealed apolipoprotein L1 (ApoL1), found in high density lipoprotein, as the lysis-inducing component of TLF, the means of uptake via haptoglobin-related protein receptor and the mechanism of resistance in T. b. rhodesiense via its serum resistance-associated (SRA) protein. The first practical steps to application of these discoveries are now in progress; transgenic animals expressing either baboon or minimally truncated human ApoL1 show resistance to both T. b. brucei and T. b. rhodesiense. This has major implications for treatment and prevention of human and animal African trypanosomiasis. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20646962     DOI: 10.1016/j.pt.2010.05.005

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  23 in total

1.  Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children.

Authors:  Patricio E Ray; Chien-An A Hu
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

2.  Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations.

Authors:  Wen-Ya Ko; Prianka Rajan; Felicia Gomez; Laura Scheinfeldt; Ping An; Cheryl A Winkler; Alain Froment; Thomas B Nyambo; Sabah A Omar; Charles Wambebe; Alessia Ranciaro; Jibril B Hirbo; Sarah A Tishkoff
Journal:  Am J Hum Genet       Date:  2013-06-13       Impact factor: 11.025

Review 3.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

Review 4.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

Review 5.  High density lipoprotein: it's not just about lipid transport anymore.

Authors:  Scott M Gordon; Susanna Hofmann; David S Askew; W Sean Davidson
Journal:  Trends Endocrinol Metab       Date:  2010-11-08       Impact factor: 12.015

Review 6.  The HDL Proteome Watch: Compilation of studies leads to new insights on HDL function.

Authors:  W Sean Davidson; Amy S Shah; Hannah Sexmith; Scott M Gordon
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-11-18       Impact factor: 4.698

Review 7.  APOL1 Kidney Disease Risk Variants: An Evolving Landscape.

Authors:  Patrick D Dummer; Sophie Limou; Avi Z Rosenberg; Jurgen Heymann; George Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Semin Nephrol       Date:  2015-05       Impact factor: 5.299

8.  A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.

Authors:  Diana Tegazzini; Rosario Díaz; Fernando Aguilar; Imanol Peña; Jesús L Presa; Vanessa Yardley; Julio J Martin; Jose M Coteron; Simon L Croft; Juan Cantizani
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 9.  Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.

Authors:  Chien-An A Hu; Edward I Klopfer; Patricio E Ray
Journal:  FEBS Lett       Date:  2012-03-08       Impact factor: 4.124

Review 10.  The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes.

Authors:  W Sean Davidson; Allison L Cooke; Debi K Swertfeger; Amy S Shah
Journal:  Curr Atheroscler Rep       Date:  2021-03-27       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.